230 - A Novel SARS-CoV-2 mRNA Virus-Like Particle Vaccine is Highly Potent and Well Tolerated in Adults in a Phase I Randomized Clinical Trial

Presenting Author(s)

• 

  Tope Oyedele, MD (he/him/his)

  Senior Medical Director
  AstraZeneca
  Gaithersburg, MD, United States

  Slides

Co-Author(s)

• RP

  Rachel Park, PharmD

  AstraZeneca
  Gaithersburg, Maryland, United States
• KM

  Kelly Morales, n/a

  Coastal Carolina Research Center
  North Charleston, South Carolina, United States
• MJ

  Manish Jain, MD

  Flourish - Great Lakes Clinical Trials
  Chicago, Illinois, United States
• LS

  Lawrence Sher, MD

  Peninsula Research Associates
  Rolling Hills Estates, California, United States
• AV

  Apinya Vutikullird, MD

  Ark Clinical Research
  Long Beach, California, United States
• TK

  Thomas Klein, MD

  Alliance for Multispecialty Research
  East Witchita, Kansas, United States
• AI

  Abby Isaacs, n/a

  AstraZeneca
  Gaithersburg, Maryland, United States
• KS

  Kathryn Shoemaker, MS

  Senior Principal Statistician
  Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
  Gaithersburg, Maryland, United States
• 

  Ann Marie Stanley, PhD

  Director
  Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
  Gaithersburg, MD, United States
• JL

  Joseph Lee, MSc

  AstraZeneca
  Gaithersburg, Maryland, United States
• CH

  Cindy Handelsman, BSc

  AstraZeneca
  Gaithersburg, Maryland, United States
• SC

  Stacey Cromer Berman, PhD

  AstraZeneca
  Gaithersburg, Maryland, United States

Presenting Author(s)

• LC

  Lee-Jah Chang, MD (he/him/his)

  Vice President, Clinical Development, Vaccines and Immune Therapies
  AstraZeneca
  Gaithersburg, Maryland, United States